Gsdmd Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GSDMD (Gasdermin D) is a gene encoding a key executor of pyroptotic cell death. The GSDMD protein forms pores in the plasma membrane, leading to cell swelling and release of inflammatory contents. This process is mediated by caspase-1, caspase-4/5 (human), and caspase-11 (mouse). Gasdermin D has emerged as a critical link between inflammasome activation and neurodegenerative cell death in AD, PD, and ALS.
| Property |
Value |
| Official Symbol |
GSDMD |
| Full Name |
GSDMD (Gasdermin D) |
| Chromosomal Location |
8p22 |
| NCBI Gene ID |
79792 |
| Ensembl ID |
ENSG00000104534 |
| UniProt ID |
Q8NHS0 |
GSDMD encodes a gasdermin family protein critical for pyroptosis:
- Pyroptosis Execution: Full-length GSDMD is cleaved by caspases to release the N-terminal domain
- Pore Formation: N-terminal domain oligomerizes and inserts into membranes, forming pores (10-20 nm)
- Inflammatory Release: Pores allow release of IL-1β, IL-18, and alarmins
- Alternative Activation: Can be activated by caspase-3 in certain contexts (caspase-7 dependent)
- GSDMD-mediated pyroptosis contributes to neuronal loss in AD
- Amyloid-β activates the NLRP3 inflammasome, leading to GSDMD cleavage
- Microglial pyroptosis propagates neuroinflammation
- GSDMD activation in dopaminergic neurons during PD progression
- Mitochondrial toxins (MPTP, 6-OHDA) induce GSDMD-dependent cell death
- α-Synuclein oligomers trigger inflammasome activation leading to pyroptosis
- Motor neuron degeneration involves GSDMD-mediated pyroptosis
- TDP-43 pathology associated with inflammasome activation
- SOD1 and FUS mutations linked to pyroptotic pathways
¶ Stroke and TBI
- Ischemic injury triggers GSDMD-dependent neuronal death
- Therapeutic potential of GSDMD inhibitors in acute brain injury
GSDMD is widely expressed:
- Brain: Neurons, microglia, astrocytes, oligodendrocytes
- Immune System: Macrophages, monocytes, neutrophils
- Other Tissues: Heart, lung, liver, kidney
| Strategy |
Approach |
Status |
| GSDMD Inhibitors |
Disulfiram, dimethyl fumarate |
Preclinical |
| Caspase-1 Inhibitors |
VX-765, pralnacasan |
Clinical trials |
| Anti-inflammatory |
IL-1β blockade |
Approved |
- Shi J, et al. (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 526(7575):660-665.
- Liu Z, et al. (2020). Gasdermin D in Alzheimer's disease: mechanism and therapeutic target. J Neuroinflammation. 17(1):234.
- Ding J, et al. (2016). Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 42(4):245-254.
- Wang Y, et al. (2021). GSDMD contributes to neurodegeneration in Parkinson's disease. Cell Death Discov. 7(1):202.
The study of Gsdmd Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.